<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02508038</url>
  </required_header>
  <id_info>
    <org_study_id>UW13090</org_study_id>
    <secondary_id>NCI-2015-01163</secondary_id>
    <secondary_id>2015-0290</secondary_id>
    <secondary_id>A536700</secondary_id>
    <secondary_id>SMPH\PEDIATRICS\PEDIATRICS</secondary_id>
    <secondary_id>Protocol Version 7/13/2021</secondary_id>
    <nct_id>NCT02508038</nct_id>
  </id_info>
  <brief_title>Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors</brief_title>
  <official_title>TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the safety of transplantation with a haploidentical donor&#xD;
      peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with&#xD;
      the immunomodulating drug, Zoledronate, given in the post-transplant period to treat&#xD;
      pediatric patients with relapsed or refractory hematologic malignancies or high risk solid&#xD;
      tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CONDITIONING REGIMENS: Patients with high-risk leukemia will receive myeloablative&#xD;
      conditioning with anti-thymocyte globulin intravenously (IV) over 4-6 hours on days -12&#xD;
      through -9, Fludarabine IV over 30 minutes on days -8 through -5, Thiotepa IV every every 12&#xD;
      hours on day -4 and Total Body Irradiation (TBI) on days -3 through -1. All other patients&#xD;
      receive reduced intensity conditioning consisting of anti-thymocyte globulin intravenously&#xD;
      (IV) over 4-6 hours on days -12 through -9, fludarabine IV over 30 minutes on days -8 through&#xD;
      -5, thiotepa IV over 4 hours every 12 hours on day -4, and melphalan IV on days -3 and -2.&#xD;
&#xD;
      PERIPHERAL BLOOD STEM CELL TRANSPLANTATION: Patients undergo TCR-alpha/beta+ and CD19+&#xD;
      depleted KIR/KIR ligand-mismatched haploidentical donor peripheral blood stem cell&#xD;
      transplantation on day 0. If the graft contains less than 4 x 10^6 CD34+ cells/kg, a second&#xD;
      HSC graft may be administered.&#xD;
&#xD;
      PROPHYLAXIS FOR GVHD: Patients receiving a graft containing &gt; 25 x 10^3 CD3+ TCR alpha/beta+&#xD;
      cells receive mycophenolate mofetil IV twice daily over 2 hours on days 1 to 30 with a rapid&#xD;
      taper. Patients with TCR alpha/beta+ cells exceeding 100,000/kg also receive tacrolimus IV&#xD;
      continuously or orally (PO) every 12 hours on days 0-90 with a taper at the discretion of the&#xD;
      Principal Investigator.&#xD;
&#xD;
      ZOLEDRONATE ADMINISTRATION: Patients will receive five doses of Zoledronate (IV) at 28 day&#xD;
      intervals beginning on Day +28 post-HSCT.&#xD;
&#xD;
      Follow-up assessments will occur after transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2016</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute graft versus host disease (GVHD)</measure>
    <time_frame>Within 100 days post-transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of graft failure</measure>
    <time_frame>At day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Immune reconstitution outcomes, as determined by immune cell analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of the CliniMACS Reagent System utilizing the CliniMACS TCRαβ-biotin and CliniMACS CD19 reagent to produce a graft with defined cell content.</measure>
    <time_frame>Day 0</time_frame>
    <description>The performance of the CliniMACS Reagent System will be evaluated by measuring the number of viable stem cells, TCRαβ+ cells, TCRγδ+ cells, NK cells and B cells in the hematopoietic stem cell graft.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Syndrome</condition>
  <condition>Rhabdomyosarcoma</condition>
  <condition>Ewing Sarcoma</condition>
  <condition>Primitive Neuroectodermal Tumor</condition>
  <condition>Osteosarcoma</condition>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>TCRαβ+/CD19+ depleted Haploidentical HSCT+ Zoledronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with high-risk leukemia (who are at least one year of age and who have not received TBI as conditioning for a previous HSCT) will receive myeloablative conditioning with ATG, Fludarabine, Thiotepa, and TBI. All other subjects will undergo a reduced-intensity conditioning regimen consisting of ATG, Fludarabine, Thiotepa, and Melphalan prior to transplant with a KIR/KIR ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCR-αβ+ and CD19+ cells. Patients will receive 5 doses of zoledronate (at 28 day intervals) starting 28 days after stem cell transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TCRαβ+/CD19+ depleted Haploidentical HSCT</intervention_name>
    <description>Patients with high-risk leukemia will receive myeloablative conditioning. All other patients will undergo a reduced-intensity conditioning with ATG, Fludarabine, Thiotepa and Melphalan followed by transplant with a KIR/KIR (Killer cell immunoglobulin-like recetptor) ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCRab+ cells and CD19+ cells using the CliniMACS System.</description>
    <arm_group_label>TCRαβ+/CD19+ depleted Haploidentical HSCT+ Zoledronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronate</intervention_name>
    <description>Given IV. Patients will receive five doses of Zoledronate (each 1.25 mg/m2 at a 28 day interval) following transplant.</description>
    <arm_group_label>TCRαβ+/CD19+ depleted Haploidentical HSCT+ Zoledronate</arm_group_label>
    <other_name>Zoledronic Acid</other_name>
    <other_name>Zometa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Availability of an eligible haploidentical donor&#xD;
&#xD;
          -  Hematologic malignancy or solid tumor&#xD;
&#xD;
          -  Patients with more than one malignancy (hematologic or solid tumor) are eligible&#xD;
&#xD;
          -  Patients with hematologic malignancy must have no HLA identical sibling or suitable&#xD;
             unrelated donor OR time needed to find an acceptable unrelated donor match would&#xD;
             likely result in disease progression such that the patient may become ineligible for&#xD;
             any type of potentially curative transplant&#xD;
&#xD;
               -  Relapsed or primary therapy-refractory AML with bone marrow blast &lt; 20%&#xD;
&#xD;
               -  High-risk refractory or relapsed ALL in patients for whom transplantation is&#xD;
                  deemed indicated (relapse occurring &lt; 30 months from diagnosis, patients&#xD;
                  relapsing after previous allogeneic transplant, relapse after 2nd remission,&#xD;
                  primary induction failure or hypodiploidy)&#xD;
&#xD;
               -  Relapsed Hodgkin lymphoma unable to achieve 2nd remission or Very Good Partial&#xD;
                  Response (VGPR) and therefore ineligible to receive autologous hematopoietic stem&#xD;
                  cell transplant (auto-HSCT)&#xD;
&#xD;
               -  Hodgkin lymphoma relapsing after auto-HSCT&#xD;
&#xD;
               -  Primary refractory or relapsed non-Hodgkin lymphoma unable to achieve 2nd&#xD;
                  remission or VGPR and therefore ineligible to receive auto-HSCT&#xD;
&#xD;
               -  Non-Hodgkin lymphoma relapsing after auto-HSCT&#xD;
&#xD;
               -  Myelodysplastic Syndrome/Myeloproliferative Syndrome&#xD;
&#xD;
        Solid Tumor&#xD;
&#xD;
          -  Patients with solid tumor must have failed or have been ineligible to receive&#xD;
             auto-HSCT or if auto-HSCT would not offer &gt; 20% chance of cure&#xD;
&#xD;
          -  Neuroblastoma&#xD;
&#xD;
               -  high risk with relapsed or refractory disease&#xD;
&#xD;
          -  Soft tissue sarcomas (Rhabdomyosarcoma, Ewing sarcoma, Primitive Neuroectodermal Tumor&#xD;
             or other high-risk extracranial solid tumors)&#xD;
&#xD;
               -  Relapsed or primary refractory metastatic&#xD;
&#xD;
               -  1st complete remission, but very high-risk features (i.e., &lt; 20% survival with&#xD;
                  conventional therapy)&#xD;
&#xD;
          -  Osteosarcoma&#xD;
&#xD;
               -  Failure to achieve Complete Response (CR) following initial therapy&#xD;
&#xD;
               -  Relapsed with pulmonary or bone metastases and did not achieve a CR with surgery&#xD;
                  and/or chemotherapy&#xD;
&#xD;
          -  Karnofsky (patients &gt; 16 years) or Lansky (patients 16 years or older) performance&#xD;
             score of ≥ 60&#xD;
&#xD;
          -  Life expectancy of ≥ 3 months&#xD;
&#xD;
          -  Patient must have fully recovered from acute toxic effects of all prior chemotherapy,&#xD;
             immunotherapy, or radiotherapy prior to entering this study&#xD;
&#xD;
          -  Study enrollment no earlier than 3 months after preceding HSCT&#xD;
&#xD;
          -  Glomerular Filtration Rate (GFR) ≥ 60 ml/min/1.73m2&#xD;
&#xD;
          -  Total bilirubin &lt; 3 mg/dL&#xD;
&#xD;
          -  ALT (alanine aminotransferase, SCPT) ≤ 5 x Upper LImit of Normal (ULN) for age&#xD;
&#xD;
          -  Ejection fraction of &gt; 40% by Multigated Acquisition Scan (MUGA) or echocardiogram&#xD;
&#xD;
          -  No evidence of dyspnea at rest&#xD;
&#xD;
          -  No supplemental oxygen requirement&#xD;
&#xD;
          -  If measured, carbon monoxide diffusion capacity (DLCO) &gt;50%&#xD;
&#xD;
          -  No severe peripheral neuropathy, signs of leukoencephalopathy or active Central&#xD;
             Nervous System (CNS) infection&#xD;
&#xD;
          -  Patients with seizure disorders may be enrolled if seizures are well controlled on&#xD;
             anticonvulsant therapy&#xD;
&#xD;
          -  If of reproductive potential, negative pregnancy test and willing to use effective&#xD;
             birth control method&#xD;
&#xD;
          -  Informed consent from patient or legal guardian (if patient is minor)&#xD;
&#xD;
        Inclusion Criteria for Donors:&#xD;
&#xD;
          -  Donor must be 18 years of age minimum, 65 years of age maximum&#xD;
&#xD;
          -  Donor must be in good general health as determined by evaluating medical provider&#xD;
&#xD;
          -  Must meet donor criteria for human cells, tissues, and cellular and tissue-based&#xD;
             products per Code of Federal Regulations 21 CFR 1271, subpart C. Specifically:&#xD;
&#xD;
               -  Donor screening in accordance with 1271.75 indicates that the donor:&#xD;
&#xD;
                    -  Is free from risk factors for, and clinical evidence of, infection due to&#xD;
                       relevant communicable disease agents and diseases; and&#xD;
&#xD;
                    -  Is free from communicable disease risks associated with xenotransplantation;&#xD;
                       and&#xD;
&#xD;
               -  The results of donor testing for relevant communicable disease agents in&#xD;
                  accordance with 1271.80 and 1271.85 are negative or nonreactive, except as&#xD;
                  provided in 1271.80(d)(1).&#xD;
&#xD;
          -  Haploidentical by HLA-typing&#xD;
&#xD;
          -  Preference will be given to donors who demonstrate KIR incompatibility with recipient&#xD;
             HLA class I ligands defined as the donor expressing a KIR gene for which the&#xD;
             corresponding HLA class I ligand is not expressed by the recipient.&#xD;
&#xD;
          -  Negative testing for relevant communicable diseases:&#xD;
&#xD;
               -  Hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
               -  Hepatitis B core antibody (Anti-HBc)&#xD;
&#xD;
               -  Hepatitis C antibody (Anti-HCV)&#xD;
&#xD;
               -  HIV 1 &amp; 2 antibody (Anti-HIV-1, 2 plus O)&#xD;
&#xD;
               -  HTLV I/II antibody (Anti-HTLV I/II)&#xD;
&#xD;
               -  RPR (Syphilis TP)&#xD;
&#xD;
               -  CMV (Capture CMV)&#xD;
&#xD;
               -  MPX for: HepB (HBV-PCR), HepC (HCV-PCR), HIV (HIV-PCR)&#xD;
&#xD;
               -  NAT for West Nile Virus (WNV-PCR)&#xD;
&#xD;
               -  T. Cruzi - EIA (Chagas)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Heart failure or uncontrolled cardiac rhythm disturbance&#xD;
&#xD;
          -  Uncontrolled, Serious Active Infection&#xD;
&#xD;
          -  Prior organ allograft&#xD;
&#xD;
          -  Significant serious intercurrent illness unrelated to cancer or its treatment not&#xD;
             covered by other exclusion criteria expected to significantly increase the risk of&#xD;
             HSCT&#xD;
&#xD;
          -  Any mental or physical condition, in the opinion of the PI (or PI designee), which&#xD;
             could interfere with the ability of the subject (or the only parent or legal guardian&#xD;
             available to care for the subject) to understand or adhere to the requirements of the&#xD;
             study&#xD;
&#xD;
          -  Enrollment in any other clinical study from screening up to Day 100 (unless PI judges&#xD;
             such enrollment would not interfere with endpoints of this study)&#xD;
&#xD;
        Exclusion Criteria for Donors:&#xD;
&#xD;
          -  Lactating females&#xD;
&#xD;
          -  Pregnant females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Capitini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenny Weiland</last_name>
    <phone>608-890-8070</phone>
    <email>PedsHemOncResearch@lists.wisc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Celeste Matsushima</last_name>
    <phone>608-890-8069</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pediatric HemOnc Main Line</last_name>
      <phone>608-263-6200</phone>
      <email>PEDSHemOncResearch@lists.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cancer Connect</last_name>
      <phone>800-622-8922</phone>
      <email>clinicaltrials@cancer.wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Capitini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://cancer.wisc.edu/</url>
    <description>University of Wisconsin Carbone Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alpha beta depleted</keyword>
  <keyword>alphabeta</keyword>
  <keyword>TCR alpha beta depleted</keyword>
  <keyword>alpha beta</keyword>
  <keyword>haploidentical</keyword>
  <keyword>Zoledronate</keyword>
  <keyword>Zoledronic acid</keyword>
  <keyword>Pediatric cancers</keyword>
  <keyword>alfa beta</keyword>
  <keyword>αβ T cell depleted HSCT</keyword>
  <keyword>alpha beta T cell and B cell depleted HSCT</keyword>
  <keyword>haploidentical HSCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

